Comment
doi: 10.1136/annrheumdis-2016-211046.
Epub 2017 Feb 8.
Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis
Affiliations
- PMID: 28179265
- DOI: 10.1136/annrheumdis-2016-211046
Item in Clipboard
Comment
Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis
Ann Rheum Dis.
2017 Oct.
No abstract available
Keywords: Cytokines; Inflammation; Psoriatic Arthritis; T Cells.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Response to: 'Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis' by Raychaudhuri et al.Ann Rheum Dis. 2017 Oct;76(10):e37. doi: 10.1136/annrheumdis-2017-211081. Epub 2017 Feb 8. Ann Rheum Dis. 2017. PMID: 28179266 No abstract available.
Comment on
-
Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.Ann Rheum Dis. 2016 Jan;75(1):311-5. doi: 10.1136/annrheumdis-2014-207201. Epub 2015 Sep 9. Ann Rheum Dis. 2016. PMID: 26353790 Free PMC article.
Similar articles
-
Response to: 'Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis' by Raychaudhuri et al.Ann Rheum Dis. 2017 Oct;76(10):e37. doi: 10.1136/annrheumdis-2017-211081. Epub 2017 Feb 8. Ann Rheum Dis. 2017. PMID: 28179266 No abstract available.
-
Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.Ann Rheum Dis. 2016 Jan;75(1):311-5. doi: 10.1136/annrheumdis-2014-207201. Epub 2015 Sep 9. Ann Rheum Dis. 2016. PMID: 26353790 Free PMC article.
-
Anti cytokine therapy in chronic inflammatory arthritis.Cytokine. 2016 Oct;86:92-99. doi: 10.1016/j.cyto.2016.07.015. Epub 2016 Aug 3. Cytokine. 2016. PMID: 27497159 Review.
-
Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis.J Immunol Res. 2018 Nov 19;2018:7897263. doi: 10.1155/2018/7897263. eCollection 2018. J Immunol Res. 2018. PMID: 30581877 Free PMC article.
-
Tofacitinib in psoriatic arthritis.Immunotherapy. 2017 Nov;9(14):1153-1163. doi: 10.2217/imt-2017-0087. Epub 2017 Oct 2. Immunotherapy. 2017. PMID: 28967798 Review.
Cited by
-
JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis and Their Clinical Significance.Curr Rheumatol Rep. 2024 Mar 16. doi: 10.1007/s11926-024-01144-x. Online ahead of print. Curr Rheumatol Rep. 2024. PMID: 38492148 Review.
-
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.Cancer Immunol Immunother. 2024 Feb 13;73(3):47. doi: 10.1007/s00262-024-03631-7. Cancer Immunol Immunother. 2024. PMID: 38349411 Free PMC article.
-
JAK Inhibitors for the Treatment of Axial Spondyloarthritis.Mediterr J Rheumatol. 2023 Jun 30;34(2):129-138. doi: 10.31138/mjr.34.2.129. eCollection 2023 Jun. Mediterr J Rheumatol. 2023. PMID: 37654636 Free PMC article. Review.
-
Upadacitinib for the treatment of psoriatic arthritis.Drugs Context. 2023 Feb 28;12:2022-11-6. doi: 10.7573/dic.2022-11-6. eCollection 2023. Drugs Context. 2023. PMID: 36876156 Free PMC article. Review.
-
Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials.Immunol Res. 2023 Aug;71(4):505-515. doi: 10.1007/s12026-023-09366-4. Epub 2023 Feb 22. Immunol Res. 2023. PMID: 36811818 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
